Table 5.

Profiles and responses of patients with metastatic pancreatic cancer in a HF10 phase I clinical trial.

Patient	Age (years)	Clinical stage	HF10 PFU/0.5 mL/days	Time	Response	Survival (days)	Side effects	Shedding
1	68	Invasive ductal carcinoma	1 × 105 × 3	1	PD	200	None	No shedding into body fluids
2	61		1 × 105 × 3	1	SD	166
3	60		5 × 105 × 3	3	SD	318
4	52		1 × 106 × 3	1	PD	98
5	73		1 × 106 × 3	3	PR	209
6	76		1 × 106 × 3	3	SD	315
7	49		1 × 106 × 6	6	PD	206
8	64		1 × 106 × 6	6	PD	113

PD, progressive disease; SD, stable disease; PR, partial response.